(VELA) Study of BLU-222 in Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

September 30, 2026

Conditions
Advanced Solid TumorsHR+ Breast CancerCCNE1 AmplificationHER2-negative Breast CancerOvarian CancerEndometrial CancerGastric CancerEsophageal AdenocarcinomaCarcinosarcoma
Interventions
DRUG

BLU-222

Oral administration

DRUG

Carboplatin

IV Infusion

DRUG

Ribociclib

Oral administration

DRUG

Fulvestrant

Intra muscular administration

Trial Locations (23)

10032

Columbia University Herbert Irving Comprehensive Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10461

Montefiore Medical Center, New York

19111

Hospital of the Fox Chase Cancer Center, Philadelphia

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20141

Instituto Europeo di Oncologia, Milan

21287

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC), Baltimore

22903

University of Virginia Comprehensive Cancer Center, Charlottesville

27514

UNC Hospitals at Chapel Hill - The University of North Carolina at Chapel Hill, Chapel Hill

34232

Florida Cancer Specialists, Sarasota

37204

Vanderbilt Breast Center at One Hundred Oaks, Nashville

48202

Henry Ford Health System, Detroit

60637

University of Chicago Medical Center, Chicago

72205

University of Arkansas for Medical Sciences, Little Rock

73104

OU Health Stephenson Cancer Center, Oklahoma City

77030

MD Anderson Cancer Center, Houston

84112

University of Utah - Huntsman Cancer Institute - PPDS, Salt Lake City

94158

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

94305

Stanford Women's Cancer Center, Stanford

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

00168

Fondazione Policlinico Universitario A Gemelli-Rome, Rome

EC1A 7BE

St Bartholomew's Hospital, London

All Listed Sponsors
lead

Blueprint Medicines Corporation

INDUSTRY

NCT05252416 - (VELA) Study of BLU-222 in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter